Literature DB >> 25559757

Severe drug-induced skin and liver injury from rivaroxaban.

Patrick Barrett1, Raj Vuppalanchi, Howard Masuoka, Naga Chalasani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25559757     DOI： 10.1007/s10620-014-3504-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  5 in total

1.  Rivaroxaban postmarketing risk of liver injury.

Authors:  Stefan Russmann; David F Niedrig; Mathias Budmiger; Caroline Schmidt; Bruno Stieger; Sandra Hürlimann; Gerd A Kullak-Ublick
Journal:  J Hepatol       Date:  2014-03-28       Impact factor: 25.083

2.  Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban.

Authors:  Evangelia Liakoni; Alexandra E Rätz Bravo; Luigi Terracciano; Markus Heim; Stephan Krähenbühl
Journal:  JAMA Intern Med       Date:  2014-10       Impact factor: 21.873

3.  Antithrombotic drugs market.

Authors:  Kritika Chaudhari; Bashar Hamad; Basharut A Syed
Journal:  Nat Rev Drug Discov       Date:  2014-07-04       Impact factor: 84.694

Review 4.  The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee.

Authors:  Pol F Boudes
Journal:  Contemp Clin Trials       Date:  2006-10       Impact factor: 2.226

5.  Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases.

Authors:  Yi-Chun Chen; Hsien-Ching Chiu; Chia-Yu Chu
Journal:  Arch Dermatol       Date:  2010-08-16
  5 in total
  5 in total

1.  Rivaroxaban-Induced Hypersensitivity Syndrome.

Authors:  Charles-Olivier Chiasson; Arnaud Canneva; François-Olivier Roy; Maxime Doré
Journal:  Can J Hosp Pharm       Date:  2017-08-31

Review 2.  Hepatotoxicity of New Oral Anticoagulants (NOACs).

Authors:  Evangelia Liakoni; Alexandra E Rätz Bravo; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2015-08       Impact factor: 5.606

3.  Comparison of bleeding risks among non-vitamin K antagonist oral anticoagulants using the Korea adverse event reporting system database.

Authors:  Young-Jin Ko; Seonji Kim; Kyounghoon Park; Minsuk Kim; Bo Ram Yang; Joongyub Lee; Mi-Sook Kim; Byung-Joo Park
Journal:  Ther Adv Drug Saf       Date:  2019-09-24

4.  Non-hemorrhage-related adverse effects of rivaroxaban.

Authors:  Eliza C Christopoulou; Theodosios D Filippatos; Moses S Elisaf
Journal:  Arch Med Sci Atheroscler Dis       Date:  2017-12-31

5.  A rare side effect seen due to the use of apixaban: Palmoplantar psoriasiform drug eruption.

Authors:  Vusal Veliyev; İbrahim Özmen; Salim Yaşar; Erol Gürsoy; Mustafa Köklü; Murat Çelik
Journal:  Anatol J Cardiol       Date:  2016-03       Impact factor: 1.596
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.